Table 2. Pearson correlation (r) between the IC50 of the different treatments and the levels of the indicated genes.
| Spinophilin | PPP1CA | PPP1CB | PPP1CC | Spinophilin/PPP1CA* | Spinophilin/PPP1CB* | Spinophilin/PPP1CC* | |
|---|---|---|---|---|---|---|---|
| metformin | −0.2567736 | −0.0305505 | 0.0471795 | 0.0072612 | −0.1737827 | −0.2997706 | −0.3934922 |
| oxaliplatin | 0.1098795 | −0.0758366 | −0.2116024 | 0.2138328 | 0.5907283 | 0.6886702 | 0.0679746 |
| cisplatin | 0.0367228 | 0.06338384 | 0.0771211 | −0.1303417 | −0.1979426 | −0.1891476 | −0.0018704 |
| etoposide | 0.0134608 | −0.0350167 | −0.0008127 | −0.0196913 | −0.0707570 | −0.0349190 | −0.0275979 |
| bortezomib | −0.0652384 | −0.3027230 | −0.0553075 | 0.2275598 | 0.7996544 | 0.4329986 | 0.0972166 |
* indicates the ratio between the levels of Spinophilin and the catalytic subunit indicated.